Thryv Australia
Thryv Therapeutics Pty Ltd
Thryv Therapeutics Pty Ltd (Thryv Australia) is a wholly owned subsidiary of Thryv Therapeutics Inc. It provides local operational oversight and coordinates Australian activities in support of Thryv Therapeutics’ international clinical development programs by working with contract research organizations (CROs), investigational sites, healthcare professionals and other partners.
Governance
Thryv Australia follows Thryv Therapeutics’ corporate governance policies and oversight processes, and meets all applicable Australian legal, regulatory and corporate obligations.
Governance
Board of Directors
Thryv Therapeutics Pty Ltd (Thryv Australia) is a wholly owned subsidiary of Thryv Therapeutics Inc. It provides local operational oversight and coordinates Australian activities in support of Thryv Therapeutics’ international clinical development programs by working with contract research organizations (CROs), investigational sites, healthcare professionals and other partners.
Paul F. Truex, MBA
Chairman of the Board
Paul Truex is the Chairman and CEO of Thryv Therapeutics, bringing nearly three decades of experience in life sciences. Over his career, he has played a pivotal role in more than $5 billion in life sciences financings and strategic transactions.
Before joining Thryv, Paul founded Anthera Pharmaceuticals, a publicly traded biotech company with significant clinical programs in cardiovascular disease, lupus, inflammation, and cystic fibrosis. He also served as Founder, President, and CEO of Peninsula Pharmaceuticals, an antibiotic development company acquired by Johnson & Johnson and Forest Laboratories for over $700 million.
Paul began his career in life sciences at Eli Lilly and Company, where he gained experience in business development, including the Lilly ICOS joint venture for the development of Cialis® and several successful out-licensing initiatives.
Paul currently serves on the boards of Feldan Therapeutics, Find Therapeutics, and Thryv. He is a former board member of Milestone (Nasdaq: MIST), Anthera (Nasdaq: ANTH), Trius (acquired), CymaBay (acquired), Eiger (EIGR), Protagonist (PTGX), and Peninsula Pharmaceuticals (acquired).
He obtained his Master of Business Administration from Indiana University and a Bachelor of Arts in Economics from the University of Waterloo. Paul also serves as an Acting Board Member for the Indiana University Johnson Center for Entrepreneurship and Innovation.
Jean-François Pariseau, MSc, MBA, ICD.D
Board Member
Jean-François Pariseau is the co-founder and Partner at Amplitude Ventures, a capital catalyst for highly innovative companies at the point of value acceleration. Amplitude partners with Canada's most promising healthcare companies, united by a vision to bring groundbreaking technologies to patients. The firm focuses on building world-class companies in precision medicine and next-generation medical devices.
Before co-founding Amplitude, Jean-François was a Partner at the Healthcare Fund of BDC Capital and an Investment Manager with CDP Capital Technology Ventures, a subsidiary of the Caisse de dépôt et placement du Québec. In these roles, he was responsible for healthcare investments in both Canada and the US.
While completing his graduate studies in biomedical sciences at a university hospital, Jean-François co-founded a consulting company specializing in regulatory affairs and a pharmaceutical product distribution company. He currently serves on the Board of Directors of Imagia-Canexia Health Inc. and Réseau Capital.
When he's not traveling to meet with entrepreneurs, Jean-François splits his time between the dojo, his bike, and acting as the personal driver for his two teenagers.
Taylor T. Kilfoil
Board Member
Taylor T. Kilfoil is one of the owners and co-founders of InClin Inc, established in San Francisco, California in 1998. He is also the Managing Director of InClin Pty Ltd in Sydney, Australia, which he founded in 2015. He brings more than 30 years of experience across the pharmaceutical, biotechnology, and contract research organization (CRO) sectors.
Throughout his career, Mr. Kilfoil has held senior consulting roles with multiple pharmaceutical and biotechnology companies, providing clinical operations and project management support for domestic and international clinical development programs across a range of therapeutic areas. He began his career in preclinical pharmacology at Syntex Research before moving into clinical research roles at CardioGenesis, Serono Australia, and Syntex Australia.
Mr. Kilfoil serves on a number of industry-related boards of directors, including Thryv Therapeutics Australia, and is a board observer for Thryv Therapeutics Inc. He holds a BS in Psychobiology from Saint John's University.
Clinical Research Activities
Thryv Australia oversees and coordinates the Australian activities of clinical studies sponsored by Thryv Therapeutics, including the ASPIRE-HF study.
Australia’s Clinical Research Environment
Australia offers a strong foundation for early-phase clinical development and innovative therapies, with experienced investigators, established research institutions and a comprehensive regulatory framework.